Top Healthcare, Biotechnology and Medical Technology Mergers & Acquisitions Completed in H1 2026

The first half of 2026 witnessed strong merger and acquisition activity across the healthcare, biotechnology, pharmaceutical, diagnostics, and medical technology industries. Companies pursued acquisitions to strengthen therapeutic pipelines, broaden diagnostic capabilities, expand geographic presence, and accelerate innovation in high-growth healthcare segments. From billion-dollar pharmaceutical transactions to strategic investments in home healthcare, medical devices, and AI-powered healthcare services, these deals demonstrate how organizations are positioning themselves for long-term growth while addressing evolving patient needs. Below are some of the most significant healthcare acquisitions completed between January and June 2026.

The following acquisitions illustrate how leading healthcare organizations leveraged strategic investments during the first half of 2026 to expand capabilities, strengthen competitive positioning, and accelerate innovation across multiple healthcare segments.

Danaher Expands Diagnostics Portfolio Through USD 9.9 Billion Acquisition of Masimo

On June 10, 2026, Danaher Corporation completed the acquisition of Masimo Corporation, following the definitive agreement announced in February 2026, in a transaction valued at approximately USD 9.9 billion, including assumed indebtedness and net of acquired cash. The acquisition strengthens Danaher's diagnostics portfolio by adding Masimo's pulse oximetry, advanced sensor technology, and AI-enabled patient monitoring solutions for acute care settings. Masimo will continue operating as a standalone company within Danaher's Diagnostics segment, supporting innovation, expanding global reach, and improving clinical decision-making and patient outcomes.

Thermo Fisher Scientific Enhances Clinical Trial Services with Clario Acquisition Through USD 8.875 Billion

On March 24, 2026, Thermo Fisher Scientific completed the acquisition of Clario Holdings, Inc. for USD 8.875 billion in cash, with additional earnout and deferred payments linked to future business performance. The transaction brings Clario into Thermo Fisher's Laboratory Products and Biopharma Services segment, enhancing its clinical research capabilities. By integrating Clario's endpoint data solutions with its existing clinical research portfolio, Thermo Fisher aims to improve patient data analysis, accelerate drug development, strengthen clinical trial decision-making, and deliver greater value to pharmaceutical and biotechnology customers.

Gilead Sciences Strengthens Oncology Portfolio with USD 7.8 Billion Acquisition of Arcellx

On April 28, 2026, Gilead Sciences completed its acquisition of Arcellx in a transaction valued at approximately USD 7.8 billion, strengthening its oncology portfolio ahead of the potential commercial launch of anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for multiple myeloma. The acquisition gives Gilead full ownership of the therapy, enabling faster development, streamlined decision-making, and the elimination of future profit-sharing, milestone, and royalty obligations. Following the merger, Arcellx became a wholly owned subsidiary of Gilead, reinforcing the company's long-term strategy to advance innovative cancer treatments.

BioMarin Strengthens Rare Disease Portfolio with USD 4.8 Billion Acquisition of Amicus Therapeutics

BioMarin Pharmaceutical Inc. completed its acquisition of Amicus Therapeutics on April 27, 2026, in an all-cash transaction valued at approximately USD 4.8 billion, marking a significant expansion of its rare disease portfolio. The acquisition adds Galafold® (migalastat) for Fabry disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe disease, while also securing U.S. rights to the Phase 3 investigational candidate DMX-200 for focal segmental glomerulosclerosis. The transaction supports BioMarin's strategy to diversify its commercial portfolio and broaden access to innovative therapies for patients with rare genetic diseases.

Shionogi Strengthens Rare Disease Business with USD 2.5 Billion RADICAVA Rights Acquisition

Shionogi & Co., Ltd. completed the acquisition of all global rights to RADICAVA (edaravone) from Tanabe Pharma Corporation on April 2, 2026, for a lump-sum payment of USD 2.5 billion. The transaction transferred intellectual property and sales rights for the amyotrophic lateral sclerosis (ALS) therapy to Shionogi, while integrating the RADICAVA team and commercial platform. The acquisition strengthens Shionogi's rare disease portfolio, expands its commercial capabilities, and supports the development and future launch of innovative therapies for patients with significant unmet medical needs.

Prestige Consumer Healthcare Strengthens Consumer Healthcare Portfolio with USD 1.045 Billion Breathe Right® Acquisition

On June 15, 2026, Prestige Consumer Healthcare Inc. announced the completion of its acquisition of the Breathe Right® brand and certain other brands from Foundation Consumer Healthcare for USD 1.045 billion, or approximately USD 900 million net of anticipated tax benefits valued at USD 150 million. Originally announced in March 2026, the transaction expands Prestige into the nasal strip category, with Breathe Right® becoming its largest brand. The acquisition supports the company's strategy to strengthen its consumer healthcare portfolio and broaden its presence across over-the-counter healthcare products.

GSK Strengthens Pulmonary Hypertension Pipeline Through 35Pharma Acquisition

On April 15, 2026, GSK acquired Canadian clinical-stage biotechnology company 35Pharma for USD 950 million. The acquisition adds HS235, a novel protein-based therapy targeting the activin receptor signaling pathway for pulmonary hypertension, to GSK's respiratory and immunology portfolio. By incorporating this differentiated therapeutic candidate into its pipeline, GSK aims to accelerate the development of new treatment options for patients with pulmonary hypertension while reinforcing its leadership in respiratory medicine.

Otsuka Expands Neuropsychiatry Portfolio Through Transcend Therapeutics Acquisition

On June 15, 2026, Otsuka Pharmaceutical finalized its acquisition of Transcend Therapeutics through Otsuka America, Inc. for an upfront payment of USD 700 million, with additional milestone payments of up to USD 525 million linked to future commercial performance. The acquisition adds TSND-201, an investigational rapid-acting treatment for post-traumatic stress disorder (PTSD), to Otsuka's neuroscience pipeline. By combining Transcend's clinical expertise with Otsuka's global development and commercialization capabilities, the company seeks to accelerate the delivery of innovative psychiatric therapies while addressing substantial unmet needs in mental healthcare.

Medtronic Acquires Scientia Vascular to Advance Stroke Care with USD 550 Million

Medtronic plc completed its acquisition of Scientia Vascular on June 12, 2026, in a transaction valued at USD 550 million, subject to customary adjustments, with additional undisclosed earn-out and milestone payments. The acquisition expands Medtronic's neurovascular portfolio by integrating Scientia's guidewire and catheter technologies with its existing access and therapeutic solutions. This strategic move is designed to simplify complex neurovascular procedures, improve physician access across the procedural workflow, and advance stroke and other neurovascular disease treatment through a more comprehensive and integrated care platform.

Biogen Expands Rare Disease and Nephrology Portfolio Through Apellis Pharmaceuticals Acquisition

Biogen completed the acquisition of Apellis Pharmaceuticals on May 14, 2026, making the complement-driven disease specialist a wholly owned subsidiary. The transaction strengthens Biogen’s healthcare portfolio by adding the commercialized therapies EMPAVELI and SYFOVRE, which generated USD 689 million in net product revenue in 2025, while expanding the company’s presence in nephrology and ophthalmology. Biogen acquired Apellis for USD 41 per share in cash, along with contingent value rights tied to future SYFOVRE sales milestones, reinforcing its long-term growth strategy in innovative treatments for serious diseases.

Conclusion

Healthcare merger and acquisition activity during the first half of 2026 reflects a clear industry focus on strengthening innovation, expanding specialized care, and improving healthcare delivery across global markets. Strategic investments in neuroscience, oncology, diagnostics, medical devices, home healthcare, women's health, and AI-enabled healthcare services demonstrate how organizations are building more comprehensive portfolios while addressing growing clinical demands. As healthcare continues to evolve, these completed acquisitions are expected to accelerate product development, improve patient access to advanced therapies and technologies, and shape the competitive landscape throughout the remainder of 2026 and beyond.